Skip to main content Skip to search Skip to main navigation

Swissmedic: Amendment to GMP Compliance by Foreign Manufacturers

Swissmedic has updated its guidance on Good Manufacturing Practice (GMP) compliance for foreign manufacturers, clarifying documentation requirements for various application types (e.g., new authorizations, type IA/IB/II changes for human and veterinary medicines).

To prove GMP compliance, documents must be provided by the Responsible Person (RP). Preferably, these should be certificates from authorities with GMP systems recognized as equivalent to Switzerland’s. If such certificates are unavailable, audit reports may be accepted under specific conditions.

Key Clarifications on Audit Reports:

  • The approved audit report should be submitted with the application. Manufacturer approval depends on this report.
  • Re-audit reports with reduced scope are accepted if missing details are addressed through an RP assessment or a RP summary based on the original complete audit covering the missing points.
  • Redacted documents (report/CAPA plan) are allowed if the assessment is not compromised.
  • Audit reports must be no older than three years and must cover the relevant product.

Inspection Reports:

Reports from recognized authorities are accepted if:

  • Not older than three years,
  • The inspection was conducted on-site, 
  • Relevant to the product in question.

Veterinary Medicines:

For notifications under Art. 39 VAZV, one copy of the GMP certificate or manufacturing authorization per foreign manufacturer is sufficient. If unavailable, an RP-prepared risk assessment may be submitted instead. Swissmedic provides guidance on the required content to ensure it proves GMP compliance.

The updated guidance took effect on 1 May 2025.


Source:

Swissmedic: General communications


Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be interested in the following articles:

EMA: Revision of Annex 6 - Manufacture of Medicinal Gases

EMA: Revision of Annex 6 - Manufacture of Medicinal Gases

EMA and PIC/S have published a concept paper announcing a targeted revision of Annex 6 Manufacture of Medicinal Gases of the EU GMP Guide. The last update dates from 2010. The revision aims to reflect current manufacturing practice, technological progress and lessons learned from the COVID-19 pandemic.

Read more
EMA: Concept Paper on the Revision of Annex 15

EMA: Concept Paper on the Revision of Annex 15

EMA and PIC/S have published a concept paper outlining a targeted revision of Annex 15 (Qualification and Validation).

Read more
What do Typical Manufacturing Processes for Sterile Products look like?

What do Typical Manufacturing Processes for Sterile Products look like?

Here's the answer:
Read more
Human Resource Management as a Key to Success

Human Resource Management as a Key to Success

The pharmaceutical industry in Germany and other countries, too, faces considerable challenges in the area of human resource management. These problems have far-reaching implications for the competitiveness and innovative power of the industry.

Read more
EMA: Reflection Paper on the Qualification of Non-Mutagenic Impurities (NMIs)

EMA: Reflection Paper on the Qualification of Non-Mutagenic Impurities (NMIs)

The EMA has published a new reflection paper outlining its current thinking on the qualification of non-mutagenic impurities (NMIs). The paper addresses recommended approaches for evaluating the safety of new or increased impurity levels, particularly when such impurities exceed the ICH Q3A/Q3B qualification thresholds and are identified after completion of non-clinical toxicology studies.

Read more
EMA: Discussions on the Revised ERA Guideline

EMA: Discussions on the Revised ERA Guideline

During the second industry stakeholder webinar on the revised guideline on environmental risk assessment (ERA) for medicinal products for human use, the European Medicines Agency (EMA) addressed key implementation challenges observed during the first year of application.
Read more
Previous
Next